Neils ChristensenNeils Christensen has a diploma in journalism from Lethbridge College and has more than a decade of reporting experience working for news organizations throughout Canada. His experiences include covering territorial and federal politics in Nunavut, Canada. He has worked exclusively within the financial sector since 2007, when he started with the Canadian Economic Press. Neils can be contacted at: 1 866 925 4826 ext. 1526 nchristensen at kitco.com @Neils_cShareDisclaimer: The views expressed ...

再次，让我们聚焦房产本身的具体情况。同样是150万的房子，其未来价值也会因地段、房龄、小区环境等因素而差异巨大。 靠近地铁、学校、 医院等优质公共资源的地段，房龄较新（例如十年以内）、小区环境优美、配套设施完善的房产，其抗跌性更强，甚至可能在五年后小幅升值。 相反，那些位于偏远地段、房龄较老（例如没有电梯的老小区）、小区环境差、周边配套设施落后的房产，五年后的价值可能仅剩100万左右，甚 至更低。 最后，回到最初的问题：五年后，你那套150万的房子值多少钱？ 答案依然是：没有确切的数字。 "普涨时代"已经过去，房地产市场的分化将日 益明显。优质房产，尤其位于人口流入较多城市、地段优越、配套完善的房产，将保持相对稳定，甚至可能小幅升值；而那些地段偏远、品质较 差的房产，其价值则可能持续下跌。 因此，对于自住型购房者而言，房屋的涨跌幅度无需过度关注，舒适的居住体验才是最重要的；而对于投资 型购房者，特别是持有位于小城市的多套房产的投资者，则需谨慎对待，避免盲目持有，应根据市场行情及时调整投资策略。 总而言之，买房需 谨慎，切勿盲目投机，理性选择，才能稳妥。 " 首先，让我们从宏观经济环境入手。当前中国经济增速放缓 ...

Will bitcoin reach $200,000 before end of next year (2026)? ...

🔥 NEW: Entrepreneur Robert Kiyosaki says he bought another Bitcoin today and reaffirms his belief that Bitcoin will be $1 million a coin one day. https://t.co/gH4H0URlSf ...

我最常用Bybit，最符合技術分析：https://bit.ly/tiabtc 全球最大幣安，累減40%手續費：https://bit.ly/tiaba 最老牌OKX歐易，佣金最高減免：https://bit.ly/tiok 最強跟單Bitget，信用卡最好用：https://bit.ly/tiabtg 兌換Discord會員：https://bit.ly/tia_discord Discord/Telegram客服：@tiahelper 推特：https://x.com/tiabitcoin 課程：https://www.tiabtc.com Telegram公告群：https://t.me/tiaalert 網格交易用Pionex：https://bit.ly/Pionextia #bitcoin #比特幣 #以太幣 #以太坊 #btc #大餅 #eth #doge #狗狗幣 #技術分析 #道氏理論 #波浪理論 #斐波拉契 #諧波形態 #自然交易理論 #自然交易法 #江恩理論 #sol #ada #bnb #xrp #dot #avax #luna #uni #大作手回憶錄 #傑西利弗莫爾 #李佛摩 #美 ...

Strategy stacks another 4,980 bitcoin as Michael Saylor boldly predicts $21 million BTC in 21 years https://t.co/nc0hG8NsO6 ...

Core Insights - Alvotech has partnered with Dr. Reddy's Laboratories to co-develop a biosimilar candidate to Keytruda, which is used for various cancer types [1][2] - Keytruda generated worldwide sales of $29.5 billion in 2024, highlighting the potential market size for the biosimilar [2] - The collaboration aims to leverage both companies' strengths in biosimilars to expedite development and enhance global market access [2] Company Developments - The agreement stipulates that both parties will share responsibilities and costs associated with the development and manufacturing of the biosimilar candidate [2][3] - Alvotech recently acquired the R&D operations of Xbrane Biopharma for approximately SEK275 million (around $27 million), which includes a biosimilar candidate based on Cimzia [4] - HSBC has upgraded Dr. Reddy's Laboratories from Hold to Buy, increasing the price forecast from $14.44 to $16.9 [4] Market Performance - As of the latest update, Dr. Reddy's Laboratories (RDY) stock rose by 6.07% to $15.65, while Alvotech (ALVO) stock decreased by 2.49% to $10.56 [7] - Analysts often utilize earnings growth and fundamental research for valuation, while some traders rely on technical analysis for stock price predictions [5][6]

一、整体趋势1 1. 短期波动，长期趋稳 2. 上半年受政策宽松（如降息、税费减免）和积压需求释放影响，核心城区二手房价格可能上涨 5%-10%。但下半年若政策收紧或经济复苏不及预期，房价可能进入横盘期，部分郊区新房价格承 压。 3. 区域分化加剧 核心区（四环内） ：因教育、医疗等稀缺资源支撑，房价抗跌性强，可能维持8-15万元/㎡高位。 近郊区域 ：改善型需求支撑，价格稳中有升，但涨幅低于核心区2。 远郊及老旧社区 ：配套不足、流动性风险较高，房价可能下跌2-4%3。 二、关键影响因素 1. 政策环境2 2. "房住不炒"基调不变，限购政策局部微调，房贷利率维持低位（首套利率3.25%-3.8%）4。政府通 过增加保障性住房供应、促进库存消化等措施稳定市场。 3. 供需关系 4. 保障性住房供给增加，人口增速放缓导致住房供需矛盾缓解，但核心区域优质房源稀缺性仍支撑 价格5。 三、区域细分预测 核心区（西城、东城、海淀） ：新房价格小幅上涨（0.1%-2%），二手房价格略有下降1。 近郊（朝阳、丰台） ：改善型需求推动，价格稳中有升。 远郊及环京区域（燕郊、固安） ：库存高、配套不足，房价可能下跌5%-10 ...

Group 1 - Elanco Animal Health announced the sale of future tiered royalties and commercial milestones related to Xdemvy for $295 million in cash, aimed at accelerating debt reduction [1] - The proceeds from the sale will help Elanco achieve a net leverage ratio of 3.9x to 4.3x adjusted EBITDA by the end of 2025 [1] - Elanco plans to repay portions of its outstanding term loans, which is expected to reduce interest expenses by approximately $10 million [2] Group 2 - Xdemvy, the first lotilaner-based product approved for human use, addresses Demodex blepharitis and is licensed to Tarsus Pharmaceuticals for exploration of human health applications [3] - The agreement covers tiered royalties on Xdemvy's U.S. net sales from April 2025 through August 2033 [3] - Elanco retains rights to all royalty payments on net sales outside the U.S. and any future human applications of lotilaner beyond ophthalmic solutions [4] Group 3 - Elanco is scheduled to release its Q1 2025 financial results, with analysts expecting adjusted earnings per share of 31 cents and sales of $1.21 billion [4] - The current stock price of Elanco is $9.75, which is below the 200-day moving average of $12.34, indicating potential bearish sentiment [6] - Recent trading saw Elanco's stock decrease by 1.03% to $9.65 [7]